Phaseline

Targets › CD13

CD13 (Aminopeptidase N): drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 3; Oncology; next expected readout Dec 2026.

Broad specificity aminopeptidase which plays a role in the final digestion of peptides generated from hydrolysis of proteins by gastric and pancreatic proteases. Also involved in the processing of various peptides including peptide hormones, such as angiotensin III and IV, neuropeptides, and chemokines. (UniProt, P15144)

Open in Phaseline: the race on CD13, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Universität MünstertTF-NGR
Tissue factor (TF) conjugated to NGR peptide targeting CD13-positive tumor vasculature
CD13Phase 3Soft Tissue SarcomaDec 2026

Conditions

Soft Tissue Sarcoma (1)

Modalities

mixed (1)

Companies

Universität Münster (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.